An FDA panel recommends expanding the use of Roche's (OTCQX:RHHBY) Lucentis for treating...

An FDA panel recommends expanding the use of Roche's (OTCQX:RHHBY) Lucentis for treating diabetic macular edema, a major cause of vision loss among those with diabetes. Lucentis is already approved for two other uses. The FDA also approves a fully automated vitamin D test that will increase Roche's roster of bone metabolism tests.